MORE THAN JUST PATIENT’S
European association taking the interests of European pALS
EupALS is an European association taking the interests of European pALS (ALS patients) to heart. We thus want to create equal rights for all the European pALS and provide better access to research and information about it.
Subscribe to our newsletter
NEWS
-
EMA announcement positive CHMP opinion for Biogen Tofersen (Qualsody)
23 February 2024 New treatment for rare motor neurone disease recommended for approval EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the… More >>
-
EUpALS in Lancet Neurology editorial November 2023
Speeding up research to improve the lives of people with ALS Advances in research over the past few years have provided a greater understanding of the pathophysiology, genetics, and risk… More >>
No post found!
MISSION
Aiming to unite all the European ALS associations…
… to fight harder together on a European scale
Stand up for the rights of all the European pALS
Create awareness on a European scale
Improve access to & information about research
Create the same rules for ALS research across Europe
ALS RESEARCH NEWS
Checkout the most recent Articles And Insights on ALS Research
-
VectorY Expands PIONEER-ALS Phase 1/2 Clinical Trial Size
29 September 2026 VectorY Expands PIONEER-ALS Phase 1/2 Clinical Trial Size VectorY Therapeutics, a clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases, announced the expansion of its ongoing,… More >>
-
Otsuka Establishes Ulefnersen Early Access Program (EAP) for Eligible People Living with FUS-ALS
22 September 2026 The program reflects Otsuka’s commitment to facilitate early access to investigational medicines outside of a clinical trial, where permitted by local regulations, for people living with rare… More >>
-
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing treatment for FUS-ALS
September 22, 2026 Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing treatment for FUS-ALS Ulefnersen demonstrated a statistically significant improvement on… More >>
-
Community Update: ASTRALS Phase 2 Trial Results in Amyotrophic Lateral Sclerosis
August 25, 2026 Novartis likes to update you on our VHB937B1 program for Amyotrophic Lateral Sclerosis (ALS). As shared previously, recruitment was completed for the ASTRALS Phase 2 clinical trial… More >>